Enveda Raises $311 Million to Advance AI-Discovered Nature-Derived Drugs
· Technology · TechCrunch
Biotech startup Enveda has secured $311 million in a Series E funding round at a $2 billion valuation. Led by Catalio Capital Management with participation from Iconiq, the fresh capital doubles the company's valuation from 12 months ago. Founded in 2019 by Viswa Colluru, Enveda uses artificial intelligence to discover potential medicines from plants and microbes rather than synthesizing them from scratch in a lab. While no AI-discovered drugs have received FDA approval yet, the startup is currently advancing several candidates into human clinical trials. Its active pipeline includes treatments targeting severe skin conditions and therapies designed to maintain weight loss after stopping GLP-1 medications.
Why it matters
The funding accelerates the clinical testing of nature-derived therapeutics, potentially bridging the gap between artificial intelligence drug discovery and approved treatments for severe medical conditions.
Read the original report — TechCrunch
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.